证券代码：603983 证券简称：丸美生物 公告编号：2025-047 广东丸美生物技术股份有限公司 关于召开2025年第三次临时股东会的通知 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、 召开会议的基本情况 (一) 股东会类型和届次 2025年第三次临时股东会 (二) 股东会召集人：董事会 (三) 投票方式：本次股东会所采用的表决方式是现场投票和网络投票相 结合的方式 (四) 现场会议召开的日期、时间和地点 召开的日期时间：2025 年 12 月 30 日 14 点 30 分 召开地点：广州市海珠区新港东路 69 号丸美大厦 11 楼会议室 (五) 网络投票的系统、起止日期和投票时间。 涉及融资融券、转融通业务、约定购回业务相关账户以及沪股通投资者的投 票，应按照《上海证券交易所上市公司自律监管指引第 1 号 — 规范运作》等有 关规定执行。 (七) 涉及公开征集股东投票权 无 二、 会议审议事项 网络投票系统：上海证券交易所股东会网络投票系统 网络投票起止时间：自2025 年 12 月 30 日 至 ...

Core Points - Company Marubi Biotechnology (603983) submitted an application for H-share issuance and listing to the Hong Kong Stock Exchange on December 11, 2025, with the application materials published on the exchange's website on the same day [1] Issuance Arrangement - The issuance is limited to specific investor groups, including Hong Kong public investors, qualified overseas investors, and domestic qualified investors eligible for overseas securities investment [2] - The listing will take place on the main board of the Hong Kong Stock Exchange [2] - The application materials are in draft form and may be updated or revised, pending approval from regulatory bodies such as the China Securities Regulatory Commission, the Hong Kong Securities and Futures Commission, and the Hong Kong Stock Exchange [2] - The company has provided links to the application materials in both Chinese and English on the Hong Kong Stock Exchange website for domestic investors to access relevant information [2]

Core Viewpoint - Marubi Biotechnology (603983.SH) has submitted an application for the issuance of H-shares and listing on the Hong Kong Stock Exchange on December 11, 2025 [1] Group 1 - The company has officially filed its application with the Hong Kong Stock Exchange [1] - The application materials for the issuance and listing have been published on the Hong Kong Stock Exchange's website [1]

Core Viewpoint - Marubi Biological has officially initiated its secondary listing process in Hong Kong, aiming to become one of the few domestic beauty giants with an "A+H" market presence, despite facing increased competition in the eye care product segment [1] Company Overview - Established in 2002, Marubi focuses on eye care research and gained prominence in 2007 with its popular eye cream, which helped it become the "first eye cream stock" upon its A-share listing in 2019 [1] - Marubi has maintained its position as the top seller in the eye care market in China for three consecutive years from 2021 to 2023 [1] Financial Performance - In 2024, Marubi reported a revenue of 2.97 billion yuan, representing a year-on-year growth of 33.44% - The net profit attributable to the parent company increased by 31.69% to 342 million yuan [1] Marketing and Brand Structure - The company has relied heavily on marketing for growth, with significant expenditures on advertising and traffic, while its research and development investment is relatively low compared to the industry [1] - The main brands "Marubi" and "Lianhuo" are experiencing growth, but the brand "Chunji" has seen a contraction [1] Competitive Landscape - Competitors such as Proya and Winona have launched similar eye care products, which has led to a squeeze on Marubi's market share [1] Regulatory Issues - In late October, Marubi was ordered to rectify issues related to financial accounting, fundraising management, and disclosure, leading to increased uncertainty regarding its IPO in Hong Kong [1]

Group 1 - Guangdong Marubi Biotechnology Co., Ltd. has submitted a listing application to the Hong Kong Stock Exchange [1] - The joint sponsors for the listing are Goldman Sachs and CITIC Securities [1]

Core Viewpoint - Marubi Biotechnology has submitted a listing application to the Hong Kong Stock Exchange, with Goldman Sachs and CITIC Securities as joint sponsors. The company ranks third in the Chinese market for recombinant collagen skincare products by retail sales in 2024, focusing on anti-aging skincare through synthetic biology technology [1][2]. Group 1: Company Overview - Marubi operates two main brands: Marubi (丸美) and L'HOTEL (恋火). The Marubi brand specializes in eye and facial anti-aging care, holding the top position in retail sales for eye care brands in China from 2021 to 2024. L'HOTEL focuses on base makeup products, ranking third among domestic base makeup brands and fifth overall in China for retail sales in 2024 [2]. - The company has developed over 80 proprietary ingredients, including recombinant double collagen and SPGβ-glucan, with more than 30 products achieving large-scale production. It operates two production bases in Guangzhou, equipped with high-density fermentation and purification processes for recombinant collagen production [2]. Group 2: Industry Position and Innovations - According to a report by Frost & Sullivan, Marubi ranks third in the recombinant collagen skincare segment in China by retail sales for 2024. The company has successfully developed recombinant double collagen, an engineered product that combines type I and type III collagen using translation pause and C-PRO loop technology [1]. - As of September 30, 2025, Marubi is the first and only company in China approved as a national research center for recombinant functional protein technology, having been recognized as a key drafting unit for the industry standard "Recombinant Soluble Collagen" by the Ministry of Industry and Information Technology [1].

Company Overview - Guangdong Marubi Biotechnology Co., Ltd. has submitted a listing application to the Hong Kong Stock Exchange, with Goldman Sachs and CITIC Securities as joint sponsors [1] - Marubi is the third largest beauty company in China's recombinant collagen skincare segment based on retail sales projected for 2024 [1] - The company focuses on providing anti-aging solutions and has over 20 years of experience in the skincare industry, leveraging synthetic biology technology [1] Product Development - Marubi has successfully developed recombinant double collagen, which combines type I (profile) collagen and type III (filling) collagen into a single molecule [1] - The company has established a comprehensive value chain covering basic research to application, having developed over 80 proprietary ingredients, with more than 30 achieving large-scale production [3] Brand Performance - Marubi and its brand "Lianhuo" are the main brands, with Marubi ranking first in China's eye care brand market from 2021 to 2024 based on retail sales [2] - Lianhuo ranks third among domestic foundation brands and fifth among all foundation brands in China, with a compound annual growth rate (CAGR) of 77.5% from 2022 to 2024 [2] Financial Performance - The company recorded revenues of RMB 1.732 billion, RMB 2.226 billion, RMB 2.970 billion, and RMB 2.450 billion for the years 2022, 2023, 2024, and the nine months ending September 30, 2025, respectively [4] - The annual profits for the same periods were RMB 167 million, RMB 278 million, RMB 342 million, and RMB 247 million [5] - Gross profits for the respective years were RMB 1.175 billion, RMB 1.560 billion, RMB 2.177 billion, and RMB 1.834 billion [6] Industry Overview - The Chinese beauty industry is projected to grow from RMB 460.3 billion in 2019 to RMB 566.3 billion in 2024, with a CAGR of 4.2% [7] - The skincare market is expected to grow from RMB 355.9 billion in 2019 to RMB 451.4 billion in 2024, with a CAGR of 4.9% [8] - The makeup market is anticipated to grow from RMB 104.5 billion in 2019 to RMB 114.8 billion in 2024, with a CAGR of 1.9% [9]

Core Viewpoint - Guangdong Marubi Biotechnology Co., Ltd. has submitted an application for listing on the Hong Kong Stock Exchange, with Goldman Sachs and CITIC Securities as joint sponsors, highlighting its position as a leading Chinese beauty company focused on anti-aging solutions [1] Company Overview - Marubi Biotechnology specializes in providing anti-aging skincare solutions and has over 20 years of experience in the industry, driven by synthetic biology technology [1] - The company emphasizes research and development, particularly in core technologies such as recombinant collagen, to innovate skincare products with anti-wrinkle, firming, and repairing effects [1] Market Position - According to a report by Frost & Sullivan, Marubi is the third largest beauty company in China in the segment of recombinant collagen skincare products, based on retail sales projected for 2024 [1]

Core Insights - Mamei Bio is a leading Chinese beauty company focused on anti-aging solutions, leveraging synthetic biology technology and over 20 years of experience in the skincare industry [4][5] - The company has developed a recombinant double collagen, a unique engineered protein that combines type I and type III collagen into a single molecule, enhancing its skincare products [4] - Mamei Bio has been recognized as the primary drafting unit for the national standard of "Recombinant Soluble Collagen" by the Ministry of Industry and Information Technology in 2023 [4] Company Overview - Mamei Bio operates two main brands: Mamei, focusing on anti-aging eye and facial care products, and Lianhuo, a cost-effective makeup brand [4] - The company has established a comprehensive value chain for core ingredients, developing over 80 proprietary components, with more than 30 achieving large-scale production [7] - Mamei Bio's production facilities are located in Guangzhou, China, and are equipped for high-density fermentation and purification processes for recombinant collagen production [7] Financial Performance - Mamei Bio's revenue for the years ending December 31 and the nine months ending September 30 are as follows: RMB 1.732 billion in 2022, RMB 2.226 billion in 2023, RMB 2.977 billion in 2024, and RMB 2.450 billion for the nine months of 2025 [8] - The company's profit for the same periods is reported as RMB 167 million in 2022, RMB 278 million in 2023, RMB 342 million in 2024, and RMB 247 million for the nine months of 2025 [9] - Gross profit figures are RMB 1.175 billion in 2022, RMB 1.560 billion in 2023, RMB 2.177 billion in 2024, and RMB 1.834 billion for the nine months of 2025 [10] Industry Overview - The Chinese beauty market is projected to grow from RMB 460.3 billion in 2019 to RMB 566.3 billion by 2024, with a compound annual growth rate (CAGR) of 4.2% [11] - The skincare segment is expected to expand from RMB 355.9 billion in 2019 to RMB 451.4 billion by 2024, with a CAGR of 4.9% [14] - The makeup segment is anticipated to grow from RMB 104.5 billion in 2019 to RMB 114.8 billion by 2024, with a CAGR of 1.9% [17]

Company Overview - Mamei Biotechnology is a leading Chinese beauty company focused on providing anti-aging solutions, leveraging synthetic biology technology and over 20 years of experience in the anti-aging skincare industry [4] - The company has successfully developed recombinant double collagen, a unique engineered collagen that combines type I and type III collagen into a single molecule, enhancing its skincare products [4] - Mamei Biotechnology has been recognized as a key drafting unit for the industry standard "Recombinant Soluble Collagen" by the Ministry of Industry and Information Technology in 2023 [4] Market Position - According to Frost & Sullivan, Mamei has ranked first in the Chinese domestic eye care brand market by retail sales from 2021 to 2024 [5] - The brand "Lianhuo" ranks third among domestic foundation brands and fifth among all foundation brands in China, with a compound annual growth rate (CAGR) of 77.5% from 2022 to 2024, the highest among the top five foundation brands [5] Product Development - Mamei has established a comprehensive value chain covering basic research to application for its core ingredients, having developed over 80 proprietary ingredients, with more than 30 achieving large-scale production [7] - The company operates two production bases in Guangzhou, which are capable of high-density fermentation and purification processes for recombinant collagen production [7] Financial Performance - The company reported revenues of RMB 1.73 billion, RMB 2.23 billion, RMB 2.97 billion, and RMB 2.45 billion for the years ending December 31, 2022, 2023, 2024, and the nine months ending September 30, 2025, respectively [9] - The annual profits for the same periods were RMB 167.43 million, RMB 277.59 million, RMB 342.36 million, and RMB 246.65 million [10] - Gross profits for the respective years were RMB 1.17 billion, RMB 1.56 billion, RMB 2.18 billion, and RMB 1.83 billion [11] Industry Overview - The Chinese beauty industry is projected to grow from RMB 460.3 billion in 2019 to RMB 566.3 billion by 2024, with a CAGR of 4.2% [12] - The skincare market is expected to expand from RMB 355.9 billion in 2019 to RMB 451.4 billion by 2024, with a CAGR of 4.9% [15] - The makeup market is anticipated to grow from RMB 104.5 billion in 2019 to RMB 114.8 billion by 2024, with a CAGR of 1.9% [18]